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Abstract: Frailty assessed using Clinical Frailty Scale (CFS) is a good predictor of adverse clinical
events including mortality in older people. CFS is also an essential criterion for determining ceilings
of care in people with COVID-19. Our aims were to assess the prevalence of frailty in older patients
hospitalised with COVID-19, their sex and age distribution, and the completion rate of the CFS tool
in evaluating frailty. Methods: Data were collected from thirteen sites. CFS was assessed routinely at
the time of admission to hospital and ranged from 1 (very fit) to 9 (terminally ill). The completion rate
of the CFS was assessed. The presence of major comorbidities such as diabetes and cardiovascular
disease was noted. Results: A total of 1277 older patients with COVID-19, aged ≥ 65 (79.9 ± 8.1) years
were included in the study, with 98.5% having fully completed CFS. The total prevalence of frailty
(CFS ≥ 5) was 66.9%, being higher in women than men (75.2% vs. 59.4%, p < 0.001). Frailty was found
in 161 (44%) patients aged 65–74 years, 352 (69%) in 75–84 years, and 341 (85%) in ≥85 years groups,
and increased across the age groups (<0.0001, test for trend). Conclusion: Frailty was prevalent in
our cohort of older people admitted to hospital with COVID-19. This indicates that older people
who are also frail, who go on to contract COVID-19 may have disease severity significant enough to
warrant hospitalization. These data may help inform health care planners and targeted interventions
and appropriate management for the frail older person.
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1. Introduction
Frailty is a pivotal factor in determining risk of poor health-related outcomes. It confers an
increased vulnerability to non-restoration of homeostasis after a stressor event [1]. Simply put, it means
that even a minor insult may result in hospitalisation and death. The Clinical Frailty Scale (CFS) is
widely used to assess frailty [2], is easy to use, and well-validated in non-COVID-19 populations aged
65 years and over [3].
COVID-19 has affected older people proportionately more than younger people [4]. At the start of
this disease, public health guidance was for all people aged 70 and older to shield or self-isolate. As the
pandemic continues, new approaches to assessing risk may be required, distinct from a blanket policy
to shield all people over a certain age. This may include the assessment of frailty, in order to better
allocate care resources to people at greater risk of negative outcomes and identify potential targets for
preventative interventions. For example, muscle strength training and protein supplementation may
delay or even reverse the progression of frailty in older people [5,6].
Current estimates of frailty are still evolving as learning about COVID-19 continues. Any estimate
is also likely to vary according to the method of frailty assessment and the population which is studied.
In this European multi-centre cohort study—the COVID-19 in Older People (COPE) study —we aim
to describe frailty prevalence estimates in more detail in older people hospitalised with COVID-19,
their sex and age distribution, and the completion rate of the CFS.
2. Materials and Methods
2.1. Study Design
The COPE study primary aims are to evaluate the association of frailty with clinical outcomes
and mortality in patients admitted to hospital with COVID-19; a full study protocol can be found
elsewhere [7]. Following appropriate ethical permissions, two rounds of data collection were performed
retrospectively between 27th February and 9th June 2020. CFS was collected routinely as per NICE
guidelines on admission to hospital [8].
2.2. Setting
Data collection was performed in twelve UK sites and one Italian site, via an established network
of clinicians with an interest in frailty (www.opsoc.eu).
2.3. Participants
We included all unselected sequential patients admitted to hospital with COVID-19. Frailty was
assessed using the CFS on admission by the admitting clinical team or by the research investigator
overseen by the Principal Investigator at each site. Criteria for diagnosis were SARS-CoV-2 positive
swabs, or a clinical diagnosis consistent with COVID-19. Site parent or research clinical teams screened
in-patient admission lists for eligibility and observed local data protection policies.
2.4. Variables
Demographic and biochemical categorical variables expressed in numbers (percentage) with
prognostic utility [9–11] were gathered and analysed. This included: age, sex, ethnicity, C-reactive
protein (CRP), estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet
in Renal Disease (MDRD) equation, and albumin. Comorbidity factors included smoking status,
coronary artery disease, diabetes mellitus, hypertension, chronic obstructive pulmonary disease
(COPD), and cardiac failure. Age groups were categorised into 65–74 years, 75–84 years, and 85 years
and over.
The CFS is an appraisal of functional and cognitive status two weeks prior to hospitalization.
This numerical scale corresponds with increasing severity, with 1 being very fit, 2 well, 3 managing well,
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4 vulnerable, 5 mildly frail, 6 moderately frail, 7 severely frail, 8 very severely frail and 9 terminally ill.
The completion rate was calculated for the CFS.
2.5. Data Analysis
The prevalence of frailty by CFS categories was presented descriptively in tabular format, according
to demographics (Table 1) and age group (Table 2). A test for trend for increasing frailty was conducted
for increasing frailty within each age group. CFS of 5 and above was considered to be frail [12,13].
Analysis was carried out using Stata v15 [14].
Table 1. Clinical Frailty Scale, demographics, and comorbidities in patients aged 65 or over admitted to
13 sites in UK and Italy—the COVID-19 in Older People (COPE) study.
CFS 1–4
N = 423
CFS 5–9
N = 854
Total
N = 1277
Sex
Female 149 (24.8) 452 (75.2) 601 (47.1)
Male 274 (40.6) 401 (59.4) 675 (52.9)
missing 0 1 1
Age
65–74 205 (56.0) 161 (44.0) 366 (28.7)
75–84 158 (31.0) 352 (69.0) 510 (39.9)
85+ 60 (15.0) 341 (85.0) 401 (31.4)
Ethnicity
White 352 (32.3) 738 (67.7) 1090 (85.4)
Asian 7 (35.0) 13 (65.0) 20 (1.6)
Black 2 (40.0) 3 (60.0) 5 (0.4)
Other 2 (25.0) 6 (75.0) 8 (0.6)
Missing 60 94 154
Smoking
Never 203 (32.7) 417 (67.3) 620 (48.6)
Ex-smoker 187 (34.2) 360 (65.8) 547 (42.8)
Current smoker 20 (27.0) 54 (73.0) 74 (5.8)
Missing 13 23 36
Diabetes
Yes 110 (30.8) 247 (69.2) 357 (28.0)
No 312 (34.1) 604 (65.9) 916 (71.7)
Missing 1 3 4
Coronary Artery Disease
Yes 97 (28.2) 247 (71.8) 344 (26.9)
No 324 (34.8) 606 (65.2) 930 (72.8)
Missing 2 1 3
Hypertension
No 174 (31.1) 386 (68.9) 560 (43.9)
Yes 77 (34.2) 148 (65.8) 225 (17.6)
Yes (on treatment) 170 (34.7) 320 (65.3) 490 (38.4)
missing 2 0 2
CRP
>40 315 (35.5) 573 (64.5) 888 (69.5)
<=40 108 (27.8) 281 (72.2) 389 (30.5)
eGFR
>60 257 (38.6) 409 (61.4) 666 (52.2)
45–59 55 (29.3) 133 (70.7) 188 (14.7)
30–44 50 (22.9) 168 (77.1) 218 (17.1)
<30 33 (22.4) 114 (77.6) 147 (11.5)
missing 28 30 58
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Table 1. Cont.
CFS 1–4
N = 423
CFS 5–9
N = 854
Total
N = 1277
Albumin
<35 237 (28.9) 583 (71.1) 820 (64.2)
>=35 162 (41.6) 227 (58.4) 389 (30.5)
Missing 24 44 68
COPD
Yes 54 (29.2) 131 (70.8) 185 (14.5)
No 316 (33.5) 628 (66.5) 944 (73.9)
Missing 53 95 148
Heart Failure
Yes 30 (18.6) 131 (81.4) 161 (12.6)
No 338 (35.0) 627 (65.0) 965 (75.6)
Missing 55 96 151
Table 2. Prevalence of Clinical Frailty Scale by Age Group and Sex in 1277 older patients admitted to
13 hospitals in COPE study.
Clinical Frailty Scale
Number *
(%) 1 2 3 4 5 6 7 8 9 Missing Total
Increasing Frailty across Age
Group (Test for Trend)
Age
65–74 12(3.3)
37
(10.1)
95
(25.9)
56
(15.3)
35
(9.6)
43
(11.7)
53
(14.5)
20
(5.5)
10
(2.7) 5 366 Reference
75–84 3(0.6)
16
(3.1)
57
(11.2)
77
(15.1)
92
(18.0)
112
(22.0)
108
(21.2)
29
(5.7)
11
(2.2) 5 510 <0.00001
85+ 0 10(2.5)
17
(4.2)
24
(6.0)
59
(14.7)
117
(29.2)
128
(31.9)
31
(7.7)
6
(1.5) 9 401 <0.00001
Sex &
Increasing Frailty Male vs.
Female
Female 4(0.7)
25
(4.2)
51
(8.5)
55
(9.2)
83
(13.8)
138
(23.0)
177
(29.5)
40
(6.7)
14
(2.3) 14 601
Male 11(1.6)
38
(5.6)
118
(17.4)
102
(15.1)
102
(15.1)
134
(19.9)
112
(16.6)
40
(5.9)
13
(1.9) 5 675 <0.001
Total 15 63 169 157 186 272 289 80 27 19 1276
* 19 patients had missing CFS values; & one patient had missing sex value.
3. Results
A total of 1277 patients were eligible and all were aged 65 years and above with a positive
diagnosis of COVID-19. The sex distribution was 52.9% male and 47.1% female. CFS was fully
completed in 98.5% of all patients. The mean (SD) age was 79.9 (8.1) years. The total prevalence of
frailty (CFS ≥ 5) was 66.9%. There was heterogeneity between the CFS across the sites, but patients
were overwhelmingly of white ethnicity (Table 1).
The number (%) of patients with CFS = 1 was 15 (1.2%) CFS = 2 63 (5.0%), CFS = 3 169 (13.5%),
CFS = 4 157 (12.6%), CFS = 5 186 (14.9%), CFS = 6 272 (21.8%), CFS = 7 289 (23.1%), CFS = 8 80 (6.4%)
and CFS = 9 46 (3.6%).
Within our population, the prevalence of frailty was 75.2% in women, and 59.4% in men (p < 0.001).
The prevalence of frailty within these three age groups was 44.6%, 69.7% and 86.9%. Frailty increased
with advancing age (p < 0.0001, test for trend). The CFS was fully completed in 98.5% of participants
(Table 2).
The prevalence of major comorbidities in our cohort was as follows: diabetes (28.0%), coronary
artery disease (26.9%), hypertension (56.1%), COPD (14.5%), and heart failure (12.6%).
4. Discussion
Our results show that the prevalence of frailty is high (66.9%), when assessed using the CFS in a
population aged 65 years and above hospitalised with COVID-19. Frailty increased with increasing
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age and was greater in females compared to males (both p < 0.001). Both these trends are similar to
previous reports in community-dwelling older people [15], but the overall prevalence is much lower at
9.9–43.7% [15,16]. This underlines how crucial assessment of frailty is, when considering the risk of
COVID-19 and subsequent management, and is likely to become more important, in the event of a
further spike in cases.
Frailty is not yet well described in COVID-19. The CFS is an important starting point on
which to base clinical judgment in a resource-scarce environment. Clinicians assessing the CFS
should understand the concept of frailty and its principles of disability, comorbidity, and cognitive
impairment [17], and it is suggested that inter-rater agreement is good [18]. This rapid assessment in
UK hospitals may have played a part in appropriate management of individual patients, as per NICE
guidelines [8]. The CFS can predict mortality for acute hospitalised older patients [19–21]. While the
CFS is used in younger populations [22] it is far more widely used and validated in patients aged 65 and
over [3], as in our current study, where it demonstrated a very high rate of completion, which would
echo these advantages.
The prevalence of frailty (CFS ≥ 5) in our study was high (66.9%), which was similar to recently
published results from a cohort comparing non-COVID-19 older patients with COVID-19 patients [23].
These figures are high but unsurprising, given the unselected nature of our cohort who are hospitalised
with COVID-19. In-patient estimates of frailty using the CFS in older people have also been high.
Hartley and colleagues found that 75% of patients aged 75 and over admitted to medical wards had
CFS ≥ 5 [24], and in other hospital-based studies, the prevalence was 36–45% [25,26]. These values
contrast with the prevalence of frailty in community-dwelling older people, where previous estimates
have ranged from 9.9–13.6% (pooled estimates) [15], to 22.4% and 43.7% over the age of 65, and over
the age of 85, respectively [16]. In a non-COVID-19 population, all-cause mortality in the severely frail
was 33%, but was much higher in the COVID-19 group at 60% [23]. This implies that frailty is not the
sole cause of mortality, rather a key factor for consideration, along with the acute illness [27].
Our study found that more women than men were frail (77.5% vs. 60.1%) (Table 1). There is
emerging evidence regarding the protective effect of the X chromosome in females [28], speculatively
due to a more robust immune system in females, although the biology of sex differences in COVID-19
is still unclear. Previously, we have shown that increasing frailty by CFS can predict mortality [29].
Although men are more commonly affected by, and hospitalised with COVID-19, women may be
frailer than men but survive for longer. Future associations should focus on the interplay between age,
sex, and frailty.
The importance of screening older people for frailty, with the intention of identifying those most
at risk is fully supported by this work. This would allow clinicians to be better prepared to assess
and triage older people in the event of the next pandemic or any other acute illness that may require
hospitalization. Due consideration should also be given to older patients who are not yet frail but
vulnerable, as to whether they warrant particular public health advice, in both hospital and community
settings. Shielding for the duration of this pandemic has been widely advised for all people over the
age of 70, but should this be the case for fit and well older people? Chronological age on its own is
not a biomarker of poor prognosis, whereas frailty is [30]. Identification of those who are vulnerable
(CFS = 4) and have mild frailty (CFS = 5) may be the starting point for clinical trials of muscle strength
training and protein supplementation, which have been found to have modest benefit in slowing the
progression of frailty in the non-COVID-19 population [5]. At this time, there is still no vaccine or
definitive treatment for COVID-19. Therefore, a parallel research focus for older people might be to
maximise risk reduction by targeted frailty prevention, and the first step in that process is identification
of those most at risk, irrespective of age.
We note that there may have been selection bias as less frail people may have remained out of
hospital due to a reduced susceptibility to the condition. Another limitation is although assessment
of the CFS was performed and overseen by clinicians with experience at collecting frailty data, we
could not account for inter-rater reliability as this was not examined. Furthermore, the impact of social
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isolating could have resulted in a change of CFS, prior to admission, as older people were likely to be
less socially active than they were previously. Finally, our results do not tell the whole story of frailty
prevalence in COVID-19, as many frail people are not admitted to hospital, and are palliated in the
community. Thus, our results do not account for frailty prevalence in the community setting.
5. Conclusions
The completion rate of the CFS was high, in a cohort of older patients admitted to hospital with
COVID-19. Frailty prevalence was high in this group, and increasing frailty was associated with
increasing age and was more prevalent in females. Every patient over the age of 65 at risk of COVID-19
should be screened for frailty. This may enable measures to be taken whilst in the community, in order
to identify targets for slowing progression of frailty and enable optimisation of physical reserves.
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